News | Cardiac Diagnostics | July 29, 2021

Bardy Carnation Ambulatory Monitor Patch Decreases Diagnosis Time and Readmissions

Readmissions were reduced to the Overlake Medical Center Emergency Department in patients with possible arrhythmia 

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambulatory Monitor (CAM) patch was presented at the 2021 Heart Rhythm Society (HRS) Conference. 

The abstract, "Accelerating Proper Evaluation of Emergency Department Patients for Arrhythmia Concerns with Discharge Use of ECG Patch Monitors," authored by Marie Yabut, Sarahi Gomes-Duarte, MA, and Eric Shipley, M.D., MBA., explores the role of the CAM ECG monitor as a solution for outpatient evaluation after presenting symptoms of cardiac arrhythmias with an inconclusive diagnosis in the emergency department. The decision to either admit or discharge patients for outpatient evaluation is typically arbitrary and there are few alternatives. The abstract concludes that emergency department adoption of ECG monitoring provided an alternative to hospital admission while providing a diagnosis three times sooner than average and dramatically reducing return visits to the emergency department.

By utilizing the CAM patch on 412 patients over the two-year period, the average time of emergency department discharge to diagnosis was 7 days compared to the previous average of 21 days. In addition, emergency department readmissions within 30 days of the initial visit decreased to 7% of study patients compared to readmission of 40% of patients who had the same type of cardiac complaints in the year prior to CAM patch availability.

According to Yabut, using the CAM patch in the emergency department was crucial in providing care for patients with cardiac arrhythmia symptoms occurring outside of normal clinic operating hours. "In the process of this study, we discovered that most patients discharged with the patch occurred outside clinic hours. The availability of the patch in the emergency department benefitted patients who would have otherwise been discharged without a cardiac monitor." Without application of the CAM patch in the emergency department, patients may experience a substantial waiting period until receiving diagnostic results and proper care.

The study also revealed that using the CAM patch as a point of care solution in the emergency department resulted in new patient referrals to the cardiology/EP department. Between 2018 and 2020, 369 patients were discharged with the CAM patch from the emergency department, and 57 of those patients were then established as cardiac patients. Additionally, 209 patients in the study had no prior cardiology care and were new referrals to Overlake Medical Center's cardiology and electrophysiology (EP) department. Due to the diagnostic capabilities of the CAM patch, 178 patients either received further diagnostic testing or a cardiac procedure.

Bardy Diagnostics is showcasing the CAM patch technology at the 2021 HRS conference in Boston and participating in the conference both virtually and in-person with an exhibitor booth offering visitors an opportunity to explore clinical case studies, experience a new interactive arrhythmia challenge, view a product demo, and discuss clinical issues and trends with the founder of Bardy Diagnostics, Gust H. Bardy, M.D. Visit www.bardydx.com/hrs2021.

For more information: www.bardydx.com

Human ECG Monitoring Outperforms AI Dependent Remote cardiac Monitoring  — HRS 2021 late-breaking study

Find more EP device news

Find more HRS 2021 conference news

 

 

Related Content

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...